Arguments that drug price controls will necessarily lead to reduced innovation raise a “false choice” that does not hold under close scrutiny of the relationship between revenues and research and development spending, according to a white paper by researchers at Bentley University’s Center for the Integration of Science and Industry and the West Health Policy Center.
“Policy makers do not need to make a false choice between reducing prices to ensure the availability of pharmaceutical products...